L3VLUP
ProSign in

BIO in the 13F filings

Bio Rad Labs Inc · CUSIP 090572207

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Q3 2026: 5 of 95 managers have filed so far; the filing deadline is 16 November 2026. Its figures cover those filers only, so it is not yet a picture of the tracked managers.

Quarter end
30 Sep 2026
the date the book describes
Filed
9 Nov 2026
latest of these filings; the earliest 9 Nov 2026
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
5
filed both Q2 2026 and Q3 2026; 0 listed it in both
Shares listed
149,033
combined, among listed positions
Reported value
$56m
combined, at the quarter end

Among the 5 comparable managers: 2 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +119,255.

Managers listing BIO in Q3 2026

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2026, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Acadian Asset Management LLC126,129$48m0.06%Added+104,7709 Nov 2026 (the filing on sec.gov)
Squarepoint Ops LLC22,904$8.7munder 0.1%Added+14,4859 Nov 2026 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2026 to Q3 2026, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
11 in Q4 2024 to 1 in Q3 2026

Tracked managers listing it, at least.

01020302014201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
BIO by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20135$24mn.a.n.a.
Q3 20134$22mn.a.n.a.
Q4 20132$13mn.a.n.a.
Q1 20143$34mn.a.n.a.
Q2 20144$33mn.a.n.a.
Q3 20145$22mn.a.n.a.
Q4 20145$41mn.a.n.a.
Q1 20158$145mn.a.n.a.
Q2 20156$170mn.a.n.a.
Q3 20157$201mn.a.n.a.
Q4 20157$186mn.a.n.a.
Q1 20166$182mn.a.n.a.
Q2 20164$188mn.a.n.a.
Q3 20164$224mn.a.n.a.
Q4 20167$317mn.a.n.a.
Q1 20179$340mn.a.n.a.
Q2 20178$298mn.a.n.a.
Q3 20174$294mn.a.n.a.
Q4 201713$478mn.a.n.a.
Q1 201813$524mn.a.n.a.
Q2 201815$657mn.a.n.a.
Q3 201816$686mn.a.n.a.
Q4 201816$498mn.a.n.a.
Q1 201915$689mn.a.n.a.
Q2 201914$614mn.a.n.a.
Q3 201916$801mn.a.n.a.
Q4 201912$585mn.a.n.a.
Q1 202012$695mn.a.n.a.
Q2 202019$1.3bnn.a.n.a.
Q3 202017$1.7bnn.a.n.a.
Q4 202013$2.2bnn.a.n.a.
Q1 202115$2.2bnn.a.n.a.
Q2 202118$2.7bnn.a.n.a.
Q3 202116$3.5bnn.a.n.a.
Q4 202119$3.3bnn.a.n.a.
Q1 202222$2.4bnn.a.n.a.
Q2 202215$1.2bnn.a.n.a.
Q3 202217$857mn.a.n.a.
Q4 202216$782mn.a.n.a.
Q1 202311$833mn.a.n.a.
Q2 202316$607mn.a.n.a.
Q3 202315$662mn.a.n.a.
Q4 202311$534m85
Q1 20247$342m46
Q2 20246$409m32
Q3 20249$708m71
Q4 202411$649m54
Q1 202510$612m63
Q2 20258$780m43
Q3 20258$983m43
Q4 20259$1.2bn1221
Q1 20268$1.2bn1814
Q2 20267$1.1bn1513
Q3 20261$48m20

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

BIO and LLY →BIO and JNJ →BIO and VRTX →Choose a stock to compare with BIO →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own BIO, latest filings →Back to the 13F Explorer →